Investigation of the pharmacodynamics and pharmacokinetics of 2-(2,4-Dimethoxyphenyl)-Imidazo-[4,5-b]-pyridine hydrochloride (AR-L 57 CL) in man
- 18 Downloads
AR-L 57 CL is an imidazole derivative which has been shown in animal studies to have a pronounced positive inotropic effect. This effect and the pharmacokinetics of AR-L 57 CL have been investigated by non-invasive methods in 8 healthy volunteers. After a single intravenous dose of 200 mg, administered as part of Phase 1 of the clinical studies, AR-L 57 CL plasma concentrations were measured by fluorimetry at intervals for up to one hour. Its inotropic action on the heart was demonstrated by changes in the systolic time intervals: QS2 = duration of electro-mechanical systole; PEP = pre-ejection period; LVET = left ventricular ejection time. The decrease in plasma concentration could be expressed in terms of an open two-compartment pharmacokinetic model. The shorter elimination phase had a t1/2 of 4 min and the longer a t1/2 of 30 min. Immediately after injection, QS2 and PEP (corrected for heart rate) as well as PEP/LVET (independent of heart rate) decreased considerably. They had returned to normal by 22 min after injection. The plasma concentrations of AR-L 57 CL of 2 – 5 µg-equivalents/ml showed a highly significant correlation with the decrease in systolic time intervals. Both systolic and diastolic blood pressure rose briefly after injection. The AV conduction time fell initially and the heart-rate increased briefly. Thus AR-L 57 CL was shown to be a short acting drug with a high degree of positive inotropic action. It did not cause bradycardia or increase atrioventricular transmission time and appeared to be easily controllable.
Key wordsPositively inotropic drug imidazole derivative i.v.-injection pharmacodynamic effects systolic time intervals plasma levels
Unable to display preview. Download preview PDF.
- 1.Ahmed, S.S., Levinson, G.E., Schwartz, C.J., Ettinger, P.O.: Systolic time intervals as measures of the contractile state of the left ventricular myocardium in man. Circulation46 559–571 (1972)Google Scholar
- 2.Diederen, H.: Unpublished results. Biberach/Riss: Dr. Karl Thomae GmbH 1974Google Scholar
- 3.Forester, W., Lewis, R.P., Weissler, A.M., Wilke, T.A.: The onset and magnitude of the contractile responses to commonly used digitalis glycosides in normal subjects. Circulation49 517–521 (1974)Google Scholar
- 4.Harris, W.S., Schoenfeld, C.D., Weissler, A.M.: Effects of adrenergic receptor activation and blockade on the systolic preejection period, heart rate and arterial pressure in man. J. clin. Invest.46 1704–1714 (1967)Google Scholar
- 5.Kutter, E., Austel, V., Diederen, W.: Deutsche Offenlegungsschrift 2305339 (1974)Google Scholar
- 6.Shapiro, W., Narahara, K., Taubert, K.: Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation42 1065–1072 (1970)Google Scholar
- 7.Wagner, J.C.: Biopharmaceutics and relevant pharmacokinetics, pp. 270–330. Hamilton, Illinois: Drug Intelligence Publications 1971Google Scholar
- 8.Weissler, A.M., Harris, W.S., Schoenfeld, C.D.: Systolic time intervals in heart failure in man. Circulation37 149–159 (1968)Google Scholar
- 9.Weissler, A.M., Snyder, J.R., Schoenfeld, C.D., Cohen, S.: Assay of digitalis glycosides in man. Amer. J. Cardiol.17 768–780 (1966)Google Scholar